About Contact Us Careers

Achondrogenesis Market Size and Forecast, by Type (Type IA, Type IB, Type II); Diagnosis; End user - Growth Trends, Key Players, Regional Analysis 2026-2035

  • Report ID: 6996
  • Published Date: Dec 02, 2025
  • Report Format: PDF, PPT
Festive Special Offer
$4550 $2450

Achondrogenesis Market Outlook:

Achondrogenesis Market size was valued at USD 2.3 billion in 2025 and is set to exceed USD 3.75 billion by 2035, expanding at over 5% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of achondrogenesis is estimated at USD 2.4 billion.

Achondrogenesis Market
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

Increasing awareness about early diagnosis and informed decision-making in cases of complicated pregnancies are the major growth factors in the market. As more people seek advanced diagnostic methods for pre-hand information about the fetus containing rare genetic diseases, demand in this sector rises. Thus, increasing incidences of rare genetic disorders are influencing healthcare organizations and soon-to-be parents to incorporate these diagnostic procedures into prenatal screening routines. According to a report published by NLM, in October 2022, around 6,000–8,000 unique rare diseases (RDs) were detected globally, 80% of which originated from genetic malformations. The report further highlighted 50–75% of the cases being pediatric onset.

Further, the rising prevalence is attracting pharmaceutical companies and laboratories to invest in the achondrogenesis market, solidifying their grip on the global preventive and diagnostic industry. On this note, the expansion of this industry is fueling the genetic testing businesses, creating large consumer bases for this sector. The enlarging marketplace is further creating business opportunities for the global players in this sector, inspiring them to introduce more innovative diagnostic solutions to control the growing population of patients with hereditary illnesses worldwide.

Key Achondrogenesis Market Insights Summary:

  • Regional Insights:

    • By 2035, North America is projected to secure over 45.7% share of the achondrogenesis market, owing to advanced diagnostic tools such as genetic testing and imaging systems.
    • APAC is anticipated to expand rapidly through 2026–2035, impelled by its wide range of applications in clinical research activities.

  • Segment Insights:

    • By 2035, the type IA segment in the achondrogenesis market is expected to command more than 48.3% share, propelled by extensive research on the underlying genetic mutation of this rare disorder.
    • Over 2026–2035, the molecular genetic testing segment is set to capture a notable market share, supported by the diverse range of end users of this advanced diagnostic technique.

  • Key Growth Trends:

    • Increased investments in genetic R&D
    • Promotional activities for fetal screening

  • Major Challenges:

    • Lack of knowledge about rare disorders
    • High cost of research and development

  • Key Players: Thermo Fisher Scientific Inc., CooperSurgical, Inc., Illumina, Inc., Siemens, Bio-Rad Laboratories, Inc., Koninklijke Philips N.V., Stryker, Invivoscribe, Inc., Abbott, INVITROGEN CORPORATION.

Global Achondrogenesis Market Forecast and Regional Outlook:

  • Market Size & Growth Projections:

    • 2025 Market Size: USD 2.3 billion
    • 2026 Market Size: USD 2.4 billion
    • Projected Market Size: USD 3.75 billion by 2035
    • Growth Forecasts: 5%

  • Key Regional Dynamics:

    • Largest Region: North America (45.7% Share by 2035)
    • Fastest Growing Region: APAC
    • Dominating Countries: United States, China, Japan, Germany, United Kingdom
    • Emerging Countries: India, South Korea, Brazil, Singapore, Australia

    • Last updated on : 2 December, 2025

Growth Drivers

  • Increased investments in genetic R&D: Research is a major contributor to the globalization of achondrogenesis market. Efforts from public health associations to improve understanding of genetic mutations and deformities have led to increased demand in this sector.  For instance, in August 2022, the National Institutes of Health (NIH) funded scientists introduced Short-read Transpore Rapid Karyotyping (STORK) for faster identification of abnormal fetal chromosomes. The same-day test can help healthcare professionals detect the cause of miscarriage and complications, improving IVF success rates by analyzing samples from various prenatal tests.
  • Promotional activities for fetal screening: As institutions and government organizations take initiatives to educate people about genetic disorders, investments in the achondrogenesis market increase. They are propelling demand in this sector by executing genetic counseling and awareness campaigns. Thus, their proactive participation in such programs heavily contributes to more adoption of these diagnostic tools. For instance, in November 2023, the School of Health Professions at UT Southwestern (UTSW) announced their plan to launch a new educational program named Master of Science in Genetic Counseling in 2024. This program was designed to increase the number of genetic counselors to cope with the demand.

Challenges

  • Lack of knowledge about rare disorders: The rarity of these diseases is itself a major setback in the achondrogenesis market. The limited patient population of RDs may dilute the concern of public health organizations or institutions, preventing them from investing in this sector. This may further result in the absence of general access to accurate diagnostic and adequate treatment solutions, limiting market growth. In addition, the lack of awareness can discourage further investments in developing new treatment options.

  • High cost of research and development: The spending on R&D may become difficult for researchers to bear, creating economic barriers in the achondrogenesis market. This obstacle can restrict progress in this sector as it lacks diversification in available options. On the other hand, expensive clinical trials may become challenging for pharmaceutical companies, preventing them from participating or investing in this sector. Moreover, regulatory hurdles can be lengthy and complex issues to resolve, causing delays in product launches.

Achondrogenesis Market Size and Forecast:

Report Attribute Details

Base Year

2025

Forecast Year

2026-2035

CAGR

5%

Base Year Market Size (2025)

USD 2.3 billion

Forecast Year Market Size (2035)

USD 3.75 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Achondrogenesis Market Segmentation:

Type Segment Analysis

Based on type, the type IA segment is set to capture over 48.3% achondrogenesis market share by 2035. Extensive research on the underlying genetic mutation of this rare disorder, having a considerably higher prevalence rate is propelling investment in this segment. The growing involvement of well-known research institutes in such studies to introduce potential faulty gene correcting or mitigating methods is also inspiring others to invest in this sector. For instance, in June 2022, a study paper was released by the ISUOG, discussing the classifications and possible symptom management solutions. The statistics revealed a significantly higher chance of 25% of having pregnancies affected with type IA and type IB achondrogenesis after one’s first incidence.    

Diagnosis Segment Analysis

In terms of diagnosis, the molecular genetic testing segment is anticipated to capture a significant share of the achondrogenesis market by the end of 2035. The diverse range of end users of this advanced diagnostic technique is the major driving factor in this segment. As genomic technology develops, innovation in associative testing methods becomes more frequent, marking progress in this segment. According to a report published by the American Society of Human Genetics (ASHG), in May 2021, the human genetics and genomics domain in the U.S. generated USD 5.2 billion in direct operations. The report further states, that this category surpassed all federal agencies by securing the single-year federal investment of USD 3.3 billion in the same year.  

Our in-depth analysis of the global achondrogenesis market includes the following segments:

Type
  • Type IA
  • Type IB
  • Type II

Diagnosis
  • Physical Examination
  • Molecular Genetic Testing
  • Chorionic Villus Sampling
  • Aminocentesis
  • Others
  • Biochemical Testing

End user
  • Specialty Clinics
  • Hospitals
  • Diagnostic Centers
  • Other
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Achondrogenesis Market - Regional Analysis

North America Market Insights

North America in achondrogenesis market is poised to hold more than 45.7% revenue share by 2035. The region’s healthcare infrastructure is enforced with advanced diagnostic tools such as genetic testing and imaging systems, which ignites demand in this sector. In addition, it has become one of the founding stones of R&D in this market due to being highly specialized in pediatric care and genomics. According to a Research Nester report, the human genomics industry of North America is estimated to hold the largest share of 45% by 2035, surged by the heavy usage of genetic expressions in drug discoveries and accelerated R&D in pharmaceuticals.

The U.S. is placing itself at the forefront of the regional achondrogenesis market by generating significant revenues from the human genetics industry. Additionally, with the supportive framework of the federal government, this country is auguring in garnering great opportunities for domestic and international leaders in this sector. According to an ASHG report, published in May 2021, the human genetics and genomics industry of the U.S. contributed to the national economy with around USD 265 billion in 2019.

Canada is investing significantly in the achondrogenesis market as a part of its strategy to make RD medication and therapeutics such as orphan drugs more accessible and effective through R&D. The country is focusing on offering all aspects of healthcare to the future generation by developing new solutions. For instance, in February 2024, the government of Canada announced a funding of USD 20 million over five years to build the Pediatric Rare Disease Clinical Trials and Treatment Network (RareKids-CAN).

APAC Market Insights

APAC is poised to register the fastest growth in the achondrogenesis market due to its wide range of applications in clinical research activities. The engaged organizations tend to invest in advanced diagnostic tools for developing better management and therapeutic interventions for genetically ill patients and high-risk pregnancies. For instance, in June 2021, Illumina partnered with Next Generation Genomic Co., Ltd. for the commercial launch of the CE-IVD VeriSeq NIPT Solution v2 in Thailand. After receiving approval from the regulatory body in November 2020, the company aimed to roll out its non-invasive testing method across Southeast Asia by offering valuable health insights during pregnancy.

The achondrogenesis market in India is gaining traction due to the growing awareness about the benefits of prenatal tests, inspiring global leaders to acquire the country’s wide marketplace.  Thus, the growing investments in the domestic medical diagnostic industry are inflating demand in this sector. According to a report published by the International Trade Administration, in April 2023, the industry of POCT diagnostic products including molecular testing in India is estimated to reach USD 70 million by 2030.   

China is aimed at revolutionizing the achondrogenesis market by introducing advanced testing solutions through biotechnology. For instance, in February 2024, a study report on new advances from the China Neonatal Genomes Project (CNGP) was published. The report highlighted the usage of genome data from 100,000 cases under this project in developing next-generation sequencing technologies to enhance patient outcomes. Evaluation of these genotype-phenotype correlations in neonatal rare diseases further revealed utility in precision medicine.

Achondrogenesis Market Size
Get Strategic Analysis by Region Now: Request Free Sample PDF

Achondrogenesis Market Players:

    The dynamics of this market are evolving with the integration of advanced technologies such as AI and cloud computing. The biotech leaders are utilizing it as a golden opportunity to leverage their progress in this field. They are also engaging in strategic collaborations & investments and product launches to solidify their position, expanding their footprint across the globe. For instance, in March 2024, Igentify launched Non-Invasive Prenatal Testing (NIPT) and Pharmacogenomics (PGx) offerings through a Digital Genetic Assistant platform. The launch was made to expand its portfolio by streamlining research and clinical workflow with better genetic data management. Such key players include:

    • Thermo Fisher Scientific Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • CooperSurgical, Inc.
    • Illumina, Inc
    • Siemens
    • Bio-Rad Laboratories, Inc.
    • Koninklijke Philips N.V.
    • Stryker
    • Invivoscribe, Inc.
    • Abbott
    • INVITROGEN CORPORATION
    • Yourgene Health

Recent Developments

  • In October 2024, Yourgene Health collaborated with Genetix to launch a local non-invasive prenatal testing service in Colombia. The partnership aimed at utilizing Yourgene’s IONA Nx NIPT Workflow to provide a CE-marked in vitro diagnostic (IVD) device to Genetix for accurate prenatal screening.
  • In August 2023, Thermo Fisher Scientific launched a new chromosomal microarray, Applied Biosystems CytoScan HD Accel array to elevate lab productivity. This launch was dedicated to bringing advancements in genetic research technologies, offering precise insights into prenatal, postnatal, and oncology research.
  • Report ID: 6996
  • Published Date: Dec 02, 2025
  • Report Format: PDF, PPT
Festive Special Offer
$4550 $2450
  • Explore a preview of key market trends and insights
  • Review sample data tables and segment breakdowns
  • Experience the quality of our visual data representations
  • Evaluate our report structure and research methodology
  • Get a glimpse of competitive landscape analysis
  • Understand how regional forecasts are presented
  • Assess the depth of company profiling and benchmarking
  • Preview how actionable insights can support your strategy

Explore real data and analysis

Download Free Sample Report

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of achondrogenesis is estimated at USD 2.4 billion.

The global achondrogenesis market size was around USD 2.3 billion in 2025 and is likely to expand at a CAGR of more than 5%, surpassing USD 3.75 billion revenue by 2035.

By 2035, North America is projected to secure over 45.7% share of the achondrogenesis market, owing to advanced diagnostic tools such as genetic testing and imaging systems.

Key players in the market include Thermo Fisher Scientific Inc., CooperSurgical, Inc., Illumina, Inc., Siemens, Bio-Rad Laboratories, Inc., Koninklijke Philips N.V., Stryker, Invivoscribe, Inc., Abbott, INVITROGEN CORPORATION.

Achondrogenesis Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Get a Free Sample

See how top U.S. companies are managing market uncertainty — get your free sample with trends, challenges, macroeconomic factors, charts, forecasts, and more.

Buy Now Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos